WITHUS PHARMACEUTICAL Co.,LTD. (KOSDAQ:330350)
South Korea
· Delayed Price · Currency is KRW 8,720.00
-190.00 (-2.13%)
At close: Mar 6, 2026
KOSDAQ:330350 Revenue
WITHUS PHARMACEUTICAL Co.,LTD. had revenue of 27.25B KRW in the quarter ending September 30, 2025, a decrease of -1.40%. This brings the company's revenue in the last twelve months to 102.11B, down -3.43% year-over-year. In the year 2024, WITHUS PHARMACEUTICAL Co.,LTD. had annual revenue of 102.72B with 28.21% growth.
Revenue (ttm)
102.11B
Revenue Growth
-3.43%
P/S Ratio
1.06
Revenue / Employee
843.86M
Employees
121
Market Cap
107.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 102.72B | 22.60B | 28.21% |
| Dec 31, 2023 | 80.12B | 15.44B | 23.87% |
| Dec 31, 2022 | 64.68B | 7.26B | 12.65% |
| Dec 31, 2021 | 57.42B | 4.01B | 7.51% |
| Dec 31, 2020 | 53.41B | 1.01B | 1.93% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samik Pharmaceutical Company LTD. | 58.88B |
| HYUNDAI BIOLAND | 129.68B |
| PHARMARESEARCH BIO | 178.19M |
| H.PIO | 257.56B |
| Sam-A Pharm. | 76.66B |
| KOREA PHARMA | 90.11B |
| Daehan Nupharm | 201.59B |
| DongKoo Bio & Pharma | 238.39B |